UPSTREAM BIO, INC. Net Income (Loss) Available to Common Stockholders, Basic
UPSTREAM BIO, INC. (UPB) reported Net Income (Loss) Available to Common Stockholders, Basic of -$143.44 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-03-26
- UPSTREAM BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$42.46M.
- UPSTREAM BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$33.75M.
- UPSTREAM BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$39.97M.
- UPSTREAM BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$27.27M.
- UPSTREAM BIO, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$143.44M.
- UPSTREAM BIO, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$76.39M.
- UPSTREAM BIO, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$38.26M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$42.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$76.21M derived: sum of 2 quarters · filed 2026-03-26 | -$116.17M derived: sum of 3 quarters · filed 2026-03-26 | -$143.44M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$33.75M 10-Q · filed 2025-11-05 | -$73.71M derived: sum of 2 quarters · filed 2025-11-05 | -$100.98M 10-Q · filed 2025-11-05 | -$122.77M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | -$39.97M 10-Q · filed 2025-08-06 | -$67.24M 10-Q · filed 2025-08-06 | -$89.03M derived: sum of 3 quarters · filed 2026-03-26 | -$110.06M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | -$27.27M 10-Q · filed 2025-05-06 | -$49.06M derived: sum of 2 quarters · filed 2026-03-26 | -$70.09M derived: sum of 3 quarters · filed 2026-03-26 | -$89.66M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | -$21.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$42.82M derived: sum of 2 quarters · filed 2026-03-26 | -$62.38M derived: sum of 3 quarters · filed 2026-03-26 | -$76.39M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$21.03M 10-Q · filed 2025-11-05 | -$40.59M derived: sum of 2 quarters · filed 2025-11-05 | -$54.60M 10-Q · filed 2025-11-05 | -$69.59M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$19.56M 10-Q · filed 2025-08-06 | -$33.57M 10-Q · filed 2025-08-06 | -$48.56M derived: sum of 3 quarters · filed 2025-08-06 | -$54.81M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$14.01M 10-Q · filed 2025-05-06 | -$28.99M derived: sum of 2 quarters · filed 2025-05-06 | -$35.25M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | -$14.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$21.24M derived: sum of 2 quarters · filed 2025-03-12 | -$38.26M 10-K · filed 2025-03-12 | |
| 2023-09-30 | -$6.25M 10-Q · filed 2024-11-07 | -$23.27M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |